Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling.

The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.

As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.

Key opinion leaders explore recent developments for bispecific antibodies, from new delivery technologies to the complexity of their pharmacokinetic profiles.

Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.

Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.

Gilead announced a $1.7 billion licence-option deal for MacroGenics’ MGD024 bispecific once Phase I trials conclude.

Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.

Pharma giant makes a major investment in improving the standards of care in B cell malignancies.

Method of delivery is just as important as discovering new medicines.

Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.

Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours